1-4 of 4
Yuki Fujioka, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Optimum Imatinib Exposure Have Possibility of Leading to Appropriate Immune Response after Imatinib Discontinuation in CML Patients

Yuki Fujioka, MD PhD, Hiroyoshi Nishikawa, MD PhD, Naoto Takahashi, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 192.
https://doi.org/10.1182/blood-2019-130300
Published: 2019
Journal Articles

Correlation between Changes in Granzyme B Expression and Time to Progression in Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide and Dexamethasone Therapy

Takahiro Kobayashi, MD PhD, Yuki Fujioka, MD PhD, Sho Ikeda, MD PhD, Hiroyoshi Nishikawa, MD PhD, Naoto Takahashi, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1792.
https://doi.org/10.1182/blood-2019-125649
Published: 2019
Journal Articles

Kinetics of Regulatory T Cells Predict the Recurrence of CML after Stopping Imatinib in Japanese CML Patiens

Yuki Fujioka, MD, Hiroyoshi Nishikawa, MD PhD, Naoto Takahashi, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4240.
https://doi.org/10.1182/blood.V128.22.4240.4240
Published: 2016
Journal Articles

Clinical Impact of Pre-Transplant Microbial Diversity on Transplant Outcomes

Shuhei Kurosawa, Noriko Doki, Masahiro Suyama, Satoshi Sasajima, Aiko Igarashi, Iyo Mimura, Hidetoshi Morita, Yuki Fujioka, MD, Hiroyoshi Nishikawa, MD PhD, Yutaka Shimazu, Wataru Suda, Masahira Hattori, Yuho Najima, Kazuhiko Kakihana, Hisashi Sakamaki, Kenya Honda, Kazuteru Ohashi
Journal: Blood
Blood (2016) 128 (22): 4577.
https://doi.org/10.1182/blood.V128.22.4577.4577
Published: 2016